Abstract
In an attempt to prolong the activity of Wy-41,747, a somatostatin analog that has been shown to improve diabetic control in type I human diabetics, the peptide was adsorbed on zinc phosphate. A flocculated suspension was produced that extended the growth hormone suppressing effects of Wy-4l, 747 in rats to at least 17 hr, compared to 2 hr when the peptide is administered dissolved in saline. A suspension prepared using somatostatin in place of Wy-41,747 was not flocculated and gave no prolongation of activity, suggesting that no adsorption occurred. The presence of histidine residues in Wy-41,747 that are not present in somatostatin is postulated to be the reason for the success of the formulation.
- Received August 14, 1984.
- Accepted November 14, 1984.
- Copyright © Parenteral Drug Association. All rights reserved.
PDA members receive access to all articles published in the current year and previous volume year. Institutional subscribers received access to all content. Log in below to receive access to this article if you are either of these.
If you are neither or you are a PDA member trying to access an article outside of your membership license, then you must purchase access to this article (below). If you do not have a username or password for JPST, you will be required to create an account prior to purchasing.
Full issue PDFs are for PDA members only.
Note to pda.org users
The PDA and PDA bookstore websites (www.pda.org and www.pda.org/bookstore) are separate websites from the PDA JPST website. When you first join PDA, your initial UserID and Password are sent to HighWirePress to create your PDA JPST account. Subsequent UserrID and Password changes required at the PDA websites will not pass on to PDA JPST and vice versa. If you forget your PDA JPST UserID and/or Password, you can request help to retrieve UserID and reset Password below.